DALLAS June 24, 2011 A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.
The study findings, reported in today's New England Journal of Medicine, mark the first time a drug therapy has led to improved kidney function for patients with type 2 diabetes and chronic kidney disease. Previous studies have identified drugs that slowed the deterioration of kidney function, said Dr. Robert Toto, director of the Houston J. and Florence A. Doswell Center for the Development of New Approaches for the Treatment of Hypertension at UT Southwestern.
"In diabetes, kidney function tends to deteriorate over time," Dr. Toto said. "No prior studies of this duration have shown what appears to be an increase in kidney function by any therapy, which makes this a very exciting development."
Type 2 is the most common form of diabetes, the leading cause of kidney failure in the U.S. Diabetics account for nearly half of all new cases of end-stage renal disease, the point at which patients require dialysis or a kidney transplant, said Dr. Toto, professor of internal medicine.
The study involved 227 adult patients with type 2 diabetes and chronic kidney disease. They were divided into four groups three receiving different dosages of bardoxolone methyl, an anti-inflammatory drug, and the fourth group receiving a placebo and acting as a control.
The patients were tracked for 56 weeks, with measurements of their kidney function taken every four weeks. At study-highlighted weeks 24 and 52, researchers saw an overall significant increase in the estimated glomerular filtration rates, which are measurements of how well the kidneys are functioning, for the patients receiving the drug.
At 56 weeks, four weeks after researchers stopped administering the drug, a third measurement showed that patients continued
|Contact: Jeff Carlton|
UT Southwestern Medical Center